Kidney, CV Outcomes Compared After Partial vs Radical Nephrectomy for RCC
The decision to undergo partial instead of radical nephrectomy should be individualized, according to investigators.
Diagnosis & Disease Information
Long-Term Data Support Frontline Avelumab and Axitinib for Advanced RCC
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
Percutaneous Cryoablation vs Partial Nephrectomy for cT1b Renal Tumors
Percutaneous cryoablation for cT1b renal tumors is associated with a higher rate of local disease recurrence compared with partial nephrectomy, new data suggest.
RCC With NF2 Mutations Associated With Metastatic Disease, Poor Survival
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Tivozanib Improves Long-Term PFS in Rel/Ref Metastatic Renal Cell Carcinoma
Tivozanib improves long-term progression-free survival, when compared with sorafenib, in patients with relapsed or refractory metastatic renal cell carcinoma, an analysis suggests.
Immunotherapy Combos Overtake TKI Monotherapy as First-Line Treatment for mRCC
Immunotherapy-based combinations have overtaken TKI monotherapy as the most-used first-line treatment for mRCC in US oncology clinics, a study suggests.
Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab
Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.
AUA Surveillance Guidelines May Improve Metastasis-Free Survival
Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.
Live Bacterial Product Improves Outcomes in Metastatic Renal Cell Carcinoma
CBM588, a live bacterial product, improves the efficacy of first-line treatment with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma, a study suggests.
Lenvatinib Plus Pembrolizumab Improves PFS2, OS in Advanced Renal Cell Carcinoma
Second progression-free survival is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...